Phone number of Dr. Oren Caspi04-7772790
Dr. Caspi is the head of the advanced heart failure program in Rambam Health Care Campus and a principal investigator at the Rappaport Faculty of Medicine, Technion-Israel Institute of Technology and the Clinical Research Institute at Rambam (CRIR).
Dr. Caspi earned his M.D. with honors from the Technion-Israel Institute of Technology in 2003. He conducted his Ph.D. studies at Prof. Gepstien’s laboratory focusing on strategies for myocardial regeneration using human stem cells. In his studies, he was among the pioneers to demonstrate the ability of human stem cell derived cardiomyocytes to improve myocardial function in the infarcted myocardium and established a technology for forming 3D human vascularized cardiac tissues. For these studies, he was awarded the Zigler prize for regenerative medicine as well as the Neufeld and the Grenadier awards.
Dr. Caspi completed his residency in internal medicine in Rambam medical center where he conducted his general cardiology fellow. He was awarded for the Daniel Shiran award for the best cardiology fellow by the Israel heart association. Dr. Caspi is a graduate of the prestigious program for heart failure expert training at the University of Zurich )UZH( and the European Society of Cardiology. Dr. Caspi was trained in advanced heart failure and mechanical circulatory support at UC San Diego Health, the center with the highest survival rate in advance heart failure in the US. In addition, he complicated focused short-term trainings in both Europe and the United States.
Dr. Caspi current basic research focuses on modeling genetic and acquired cardiomyopathies using the induced pluripotency technology, and on stem cell based myocardial regeneration. Dr. Caspi’s clinical research focuses on optimizing the clinical management of acute heart failure patients using machine learning and causal inference methodologies.
Dr. Caspi is a member of the European Society of Cardiology and a member in the ESC working group for myocardial regeneration.